Supernus achieved record total revenues of $211.6 million in Q4 2025, a 21% increase year-over-year. Despite the revenue growth, the company reported a GAAP operating loss and net loss for the quarter, primarily due to acquisition-related costs from the Sage Therapeutics transaction. However, non-GAAP adjusted operating earnings remained stable at $48.5 million.
Record Q4 total revenues of $211.6 million, up 21% compared to Q4 2024.
Combined revenues from four growth products (Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO) grew 45% to $161.3 million.
Successful acquisition of Sage Therapeutics, Inc. and the U.S. launch of ONAPGO for Parkinson's disease.
Resumption of new patient initiation for ONAPGO in Q1 2026 following supply chain improvements.
For the full year 2026, Supernus expects total revenues between $840 million and $870 million, with adjusted operating earnings significantly higher than GAAP operating earnings.
Analyze how earnings announcements historically affect stock price performance